ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026
Real-world challenges of 4-month rifapentine-moxifloxacin TB regimen: High hyperbilirubinemia in Thailand.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The four-month rifapentine-moxifloxacin (HPMZ) regimen is an alternative to the standard six-month tuberculosis treatment. While clinical trials confirm its efficacy, real-world data, especially in Asian populations, are limited. This study evaluates the effectiveness and tolerability of HPMZ in Thailand. Methods: A prospective study was conducted at the Central Chest Institute of Thailand (September 2023-June 2025) in drug-susceptible TB patients. The HPMZ regimen included daily rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and weight-based pyrazinamide for eight weeks, followed by rifapentine, moxifloxacin, and isoniazid for nine weeks. Patients were monitored for adverse events (AEs). Results: Fourteen participants (median age 54 years, weight 55.35 kg) received a mean rifapentine dose of 21.26 mg/kg. Hyperbilirubinemia was the most common AEs, leading to treatment discontinuation in 78.57%. Grade 3 hyperbilirubinemia occurred in 57.14%, with a mean peak bilirubin level of 3.03 mg/dL. Rifapentine overexposure was observed, with five patients showing a mean maximum plasma concentration (Cmax) of 41.89 ± 10.42 μg/mL. Conclusion: The high incidence of hyperbilirubinemia suggests a fixed 1200 mg rifapentine dose may not be suitable for lower-weight populations. Weight-based rifapentine dosing and standardized ADR management are crucial for broader implementation. Larger studies are needed to refine dosing and evaluate effectiveness and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.